Skip to main content
Publications
Ashraf M, Rageh A, Gilbert M, Tolls D, Fleming A , Souka A, El-Baha S, Cavallerano JD, Sun JK, Aiello LP, Silva PS. Factors affecting predominantly peripheral lesion identification and grading . Transl Vis Sce Techn. 2021 Jun 1;10(7):6. doi: 10.1167/tvst.10.7.6
Hunter JE, Zepp JM, Gilmore MJ, Davis JV, Esterberg EJ , Muessig KR, Peterson SK, Syngal S, Acheson LS, Wiesner GL, Reiss JA, Goddard KA. Universal tumor screening for Lynch syndrome: assessment of the perspectives of patients with colorectal cancer regarding benefits and barriers . Cancer. 2015 Sep 15;121(18):3281-9. doi: 10.1002/cncr.29470
Burris HA, Lebrun F, Rugo HS, Beck T, Piccart M, Neven P, Baselga J, Petrakova K, Hortobagyi GN, Komorowski A, Chouinard E, Young R, Gnant M, Pritchard KI, Bennett L , Ricci J-F, Bauly H, Taran T, Sahmoud T, Noguchi S. Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial . Cancer. 2013 Mar 15;119(10):1908-15.
Maurel J, Martins AS, Poveda A, Lopez-Guerrero JA, Cubedo R, Casado A, Martinez-Trufero J, Ramon Ayuso J, Lopez-Pousa A, Garcia-Albeniz X , Garcia del Muro X, de Alava E. Imatinib plus low-dose doxorubicin in patients with advanced gastrointestinal stromal tumors refractory to high-dose imatinib: a phase I-II study by the Spanish Group for Research on Sarcomas . Cancer. 2010 Aug 1;116(15):3692-701. doi: 10.1002/cncr.25111